NCT04115306View on ClinicalTrials.gov

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

PMD-026

Investigational Drug

DRUG

fulvestrant

SERDs

Trial Locations (8)

33612

RECRUITING

Moffitt Cancer Center, Tampa

43210

RECRUITING

Ohio State University, Columbus

48334

RECRUITING

Profound Research, Farmington Hills

77030

RECRUITING

Oncology Consultants, Houston

78229

RECRUITING

South Texas Accelerated Research Therapeutics, San Antonio

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

90095

RECRUITING

University of California, Los Angeles (UCLA), Los Angeles

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

Sponsors
All Listed Sponsors
lead

Phoenix Molecular Designs

INDUSTRY

NCT04115306 - Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter